LRMR Valuation

Larimar Therapeutics Inc

Add to Watchlist

Advanced Chart

3.620

-0.29(-7.417%)1D

Overview
Forecast
Valuation
Earnings

LRMR Relative Valuation

LRMR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LRMR is overvalued; if below, it's undervalued.

Historical Valuation

Larimar Therapeutics Inc (LRMR) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.91. The fair price of Larimar Therapeutics Inc (LRMR) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：3.61

Fair

-2.06

Trailing

Forward

-1.49

EV/EBITDA

Larimar Therapeutics Inc. (LRMR) has a current EV/EBITDA of -1.49. The 5-year average EV/EBITDA is -1.16. The thresholds are as follows: Strongly Undervalued below -4.25, Undervalued between -4.25 and -2.70, Fairly Valued between 0.39 and -2.70, Overvalued between 0.39 and 1.93, and Strongly Overvalued above 1.93. The current Forward EV/EBITDA of -1.49 falls within the Historic Trend Line -Fairly Valued range.

-1.51

EV/EBIT

Larimar Therapeutics Inc. (LRMR) has a current EV/EBIT of -1.51. The 5-year average EV/EBIT is -1.85. The thresholds are as follows: Strongly Undervalued below -4.93, Undervalued between -4.93 and -3.39, Fairly Valued between -0.31 and -3.39, Overvalued between -0.31 and 1.23, and Strongly Overvalued above 1.23. The current Forward EV/EBIT of -1.51 falls within the Historic Trend Line -Fairly Valued range.

0.00

Larimar Therapeutics Inc. (LRMR) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

-2.71

P/OCF

Larimar Therapeutics Inc. (LRMR) has a current P/OCF of -2.71. The 5-year average P/OCF is -2.70. The thresholds are as follows: Strongly Undervalued below -7.62, Undervalued between -7.62 and -5.16, Fairly Valued between -0.24 and -5.16, Overvalued between -0.24 and 2.22, and Strongly Overvalued above 2.22. The current Forward P/OCF of -2.71 falls within the Historic Trend Line -Fairly Valued range.

-2.71

P/FCF

Larimar Therapeutics Inc. (LRMR) has a current P/FCF of -2.71. The 5-year average P/FCF is -1.42. The thresholds are as follows: Strongly Undervalued below -5.03, Undervalued between -5.03 and -3.23, Fairly Valued between 0.38 and -3.23, Overvalued between 0.38 and 2.18, and Strongly Overvalued above 2.18. The current Forward P/FCF of -2.71 falls within the Historic Trend Line -Fairly Valued range.

Larimar Therapeutics Inc (LRMR) has a current Price-to-Book (P/B) ratio of 2.09. Compared to its 3-year average P/B ratio of 1.88 , the current P/B ratio is approximately 10.98% higher. Relative to its 5-year average P/B ratio of 2.02, the current P/B ratio is about 3.52% higher. Larimar Therapeutics Inc (LRMR) has a Forward Free Cash Flow (FCF) yield of approximately -27.74%. Compared to its 3-year average FCF yield of -21.26%, the current FCF yield is approximately 30.50% lower. Relative to its 5-year average FCF yield of -27.22% , the current FCF yield is about 1.92% lower.

1.93

P/B

Median3y

1.88

Median5y

2.02

-27.67

FCF Yield

Median3y

-21.26

Median5y

-27.22

Competitors Valuation Multiple

The average P/S ratio for LRMR's competitors is 2.06, providing a benchmark for relative valuation. Larimar Therapeutics Inc Corp (LRMR) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

LRMR.O

Larimar Therapeutics Inc

Candel Therapeutics Inc

Loss

317.84M

ZYBT.O

Zhengye Biotechnology Holding Ltd

DiaMedica Therapeutics Inc

Loss

296.69M

FHTX.O

Foghorn Therapeutics Inc

10.30

9.71%

286.04M

Performance Decomposition

Market capitalization of LRMR increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of LRMR in the past 1 year is driven by Unknown.